Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a primary subject of discussion.
May 2021
In September 2020, the FDA announced that it would require the manufacturers of all benzodiazepines to update the black-box warning (the strongest warning that the agency can require) for these drugs to describe risks of abuse, addiction and other related adverse reactions. Such action was long overdue.
December 2018
Learn how patients can initiate a discussion with their doctors to begin the process of weaning off benzodiazepines, a class of highly overprescribed sedative hypnotic drugs primarily used to treat anxiety and insomnia.
September 2016
Readers of Worst Pills, Best Pills News are aware that all benzodiazepine tranquilizers and sleeping pills, except for alprazolam (XANAX) and clonazepam (KLONOPIN), are now considered Do Not Use drugs. In this article, we explain why combining these drugs with opioid painkillers could kill you.
July 2014
For many years, Public Citizen’s Health Research Group has recommended against using tranquilizers and sleeping pills to treat insomnia and anxiety. This article presents new evidence linking use of these drugs to an increased risk of premature death.
December 2013
We oppose the use of all sleeping pills, based on experts’ findings that “nonpharmacological treatments not only cause fewer side effects, but … can sustain long-term improvements more successfully than pharmacological treatments.” Read this article to learn about some suggested nondrug approaches.
January 2013
Find out the names of 11 different drugs in this popular family of tranquillizers and sleeping pills that can increase the risk of dementia 30 to 40 percent in older adults.
April 2009
This second article about drug-induced dementia or delirium lists and discusses an additional 79 drugs that can cause these reversible kinds of mental deterioration. The two articles collectively review 136 drugs that can cause these serious side effects, especially in older people.